Development of Human Monoclonal Antibodies to Rabies

Dorfman, N. A.; Dietzschold, Bernhard; Kajiyama, Wataru; Fu, Zhen F.; Koprowski, Hilary; Notkins, Abner Louis

doi:10.1089/hyb.1994.13.397

Cited by 14 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, none of these approaches is likely to graduate to use in clinical settings in the near future. and to ensure in vivo protection in a Syrian hamster rabies challenge model; they have also been demonstrated to be effective in phase I trials in humans [129][130][131][132][133]. The successful development of such antibodies would help to ensure the supply of life-saving biological drugs to people exposed to rabies, at a reasonable cost.…”

Section: Future Developmentsmentioning

confidence: 99%

Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteurs Discovery

Dacheux¹,

Delmas²,

Bourhy

2011

IDDT

View full text Add to dashboard Cite

Rabies remains one of the most ancient and deadly of human infectious diseases. This viral zoonosis is transmitted principally by the saliva of infected dogs, inducing a form of encephalomyelitis that is almost invariably fatal. Since the first implementation, by Louis Pasteur in 1885, of an efficient preventive post-exposure treatment, more effective protocols and safer products have been developed, providing almost 100% protection if administered early enough. However, this disease still represents a major, but neglected public health problem, with an estimated 55,000 human deaths due to rabies reported each year, mostly in Africa and Asia. Once the first clinical signs appear, there is no effective treatment. A ray of hope emerged in 2004, with the report of a patient recovering from rabies after aggressive, innovative treatment. However, this case was not clearly reproduced and the identification of targets for antiviral treatment in cases of rabies infection remains a major challenge. In this context, this review presents the state-of-the art in the prevention and curative treatment of human rabies. We begin by describing the viral etiological agent and the disease it causes, to provide an essential background to rabies. An overview of the post-exposure prophylaxis of rabies in humans is then given, from its initial implementation to possible future developments. Finally, an analysis of the various antiviral compounds tested in rabies in vitro, in animal models or in humans is presented, focusing in particular on potential new strategies.

show abstract

Section: Future Developmentsmentioning

confidence: 99%

Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteurs Discovery

Dacheux¹,

Delmas²,

Bourhy

2011

IDDT

View full text Add to dashboard Cite

show abstract

“…L'utilisation des AcM murins est moins avancée et pose potentiellement des problèmes anaphylactiques (Muhamuda et al, 2007). La combinaison d'AcM humains présentant les mêmes capacités neutralisantes que les HRIG semble une bonne alternative (Dorfman et al, 1994 ;Champion et al, 2000 ;Bakker et al, 2005Bakker et al, , 2008Sloan et al, 2007). Ces anticorps sont sélectionnés pour présenter des spécificités et des fonctionnalités complémentaires.…”

Section: Les Produits En Développementunclassified

L'immunothérapie antirabique passive d'hier et d'aujourd'hui

Bourhy¹,

Dacheux²,

Ribadeau-Dumas³

2010

Biologie Aujourd'hui

View full text Add to dashboard Cite

Rabies is a fatal disease transmitted by infected animals by bite, scratch, licking on broken skin or contamination of mucosis by saliva. The regimen of post-exposure prophylaxis for people not previously vaccinated, that is currently recommended by WHO, consists of a combination of wound cleaning, active immunization and passive immunization when the exposure is of category 3. Most of the products available on the market, in particular human rabies immunoglobulins, highly purified equine rabies immunoglobulins and the derived F(ab')(2) fragments, are now characterized by high potency and safety. Although the interest of passive anti-rabies immunization was first demonstrated in the first half of the 20th century, there is still an inadequate supply of these products to the target populations mostly in developing countries. Therefore, it is urgent to set-up training and information actions for healthcare personnel on the need to use passive immunotherapy and the lack of adverse effects of the related products. For the future, we hope that a scale up of production and a lower price will improve the accessibility to these products. The development of new products based on monoclonal antibodies and molecular biology, and which may be cheaper, is promising.

show abstract

“…Briefly, human rabies immunoglobulins (HRIG) are used in combination with rabies vaccination for a known or suspected rabies exposure, administered intravenously as well as directly into the suspected exposure site (see the chapter by T. Nagarajan et al, this volume). Native human antibodies have been cloned that are capable of neutralizing the virus in vitro and in vivo; most of these are reactive with the rabies glycoprotein (Dietzschold et al 1990;Gebauer and Lindl 1990;Lafon et al 1990;Ueki et al 1990;Enssle et al 1991;Dorfman et al 1994;T. Nagarajan et al, this volume).…”

Section: Rabies Virusmentioning

confidence: 99%

Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics

Dessain

Adekar

Berry³

2008

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Native human antibodies are defined as those that arise naturally as the result of the functioning of an intact human immune system. The utility of native antibodies for the treatment of human viral diseases has been established through experience with hyperimmune human globulins. Native antibodies, as a class, differ in some respects from those obtained by recombinant library methods (phage or transgenic mouse) and possess distinct properties that may make them ideal therapeutics

show abstract

Development of Human Monoclonal Antibodies to Rabies

Cited by 14 publications

References 17 publications

Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteurs Discovery

Human Rabies Encephalitis Prevention and Treatment: Progress Since Pasteurs Discovery

L'immunothérapie antirabique passive d'hier et d'aujourd'hui

Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics

Contact Info

Product

Resources

About